Upstream Bio, Inc. (UPB) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, specifically severe respiratory disorders. The company's sole product candidate is verekitug, a monoclonal antibody targeting the Thymic Stromal Lymphopoietin (TSLP) receptor. This report covers the quarterly period ended June 30, 2025. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $0.9 million | $0.5 million | $1.5 million | $1.2 million |
| Net Loss | $(40.0) million | $(14.7) million | $(67.2) million | $(25.6) million |
| Net Loss Per Share (Basic/Diluted) | $(0.74) | $(6.50) | $(1.25) | $(11.18) |
| Research & Development Expenses | $37.9 million | $14.1 million | $63.7 million | $25.8 million |
| General & Administrative Expenses | $7.4 million | $4.0 million | $14.2 million | $7.9 million |
| Cash, Cash Equivalents & Short-Term Investments | $393.6 million (as of June 30, 2025) | |||
| Accumulated Deficit | $(258.0) million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased by 84% in Q2 2025 compared to Q2 2024, driven by reimbursable costs under the Maruho License Agreement for Phase 2 clinical trial activities.
- Expense Surge: Total operating expenses increased by 151% in Q2 2025 ($45.3 million) compared to Q2 2024 ($18.1 million).
- R&D: Increased by $23.8 million, primarily due to the initiation of the Phase 2 Long-Term Extension (LTE) study for severe asthma, planning for the COPD Phase 2 trial, and a significant increase in manufacturing costs ($8.6 million) for Phase 3 clinical material.
- G&A: Increased by $3.4 million, driven by higher personnel expenses and professional fees.
- Interest Income: Increased to $4.4 million in Q2 2025 from $2.9 million in Q2 2024 due to higher cash balances invested in money market funds and U.S. government securities.
- One-Time Items: The prior year period included a $2.9 million gain from the change in fair value of a preferred stock tranche right liability, which was settled in April 2024 and did not recur in 2025.
Guidance, Outlook, and Risks
- Clinical Milestones:
- CRSwNP: Enrollment completed in January 2025; top-line data expected in Q3 2025.
- Severe Asthma: Enrollment completed in June 2025; top-line data expected in Q1 2026.
- COPD: Phase 2 trial initiated in July 2025.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and short-term investments ($393.6 million) are sufficient to fund operations through 2027. No immediate financing is required, but additional capital will be needed for future growth.
- Key Risks:
- Single Product Dependency: The company relies entirely on the success of verekitug.
- Third-Party Reliance: Dependence on third-party manufacturers (e.g., WuXi Biologics) and CROs for clinical trials and drug supply.
- Regulatory Uncertainty: Risks associated with FDA/EMA approval processes and the potential for clinical trial failures.
- Geopolitical/Trade: Potential impact of U.S. legislation (e.g., BIOSECURE Act) on relationships with Chinese biotechnology partners.
Investor Verification Checklist
- Verify the timeline for top-line data release for the CRSwNP Phase 2 trial (expected Q3 2025) and the Severe Asthma Phase 2 trial (expected Q1 2026).
- Confirm the status of the COPD Phase 2 trial initiation and enrollment progress following the July 2025 start date.
- Review the specific terms of the Maruho License Agreement to understand the sustainability of collaboration revenue.
- Assess the company's manufacturing strategy and any potential risks related to reliance on WuXi Biologics in light of U.S. legislative proposals.
- Monitor cash burn rate relative to the stated runway through 2027, given the significant increase in R&D spending.